Abeona Therapeutics Inc vs NetEase Inc — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while NetEase Inc trades at $124.16 (market cap $82.75B). The key difference: NetEase Inc is far larger — about 196.5× Abeona Therapeutics Inc's market cap, and NetEase Inc pays a 2.36% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NTES | |
|---|---|---|
Market Cap | $421.19M | $82.75B |
Sector | Health | Media |
52-Week High | $7.45 | $159.34 |
52-Week Low | $4.17 | $109.26 |
Enterprise Value | $276.10M | $59.05B |
Dividend Yield | — | 2.36% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
NetEase (NTES) trades at $124.26, down 6.86% over 24 hours, with a P/E of 16.31 and P/S of 4.86. Recent earnings show a beat in Q1 2026 but misses in prior quarters. The company maintains strong profitability with a net income margin of 29.84% and ROE of 22.12%. Technical indicators signal a bullish trend, supported by positive analyst sentiment with 82% buy ratings.
The outlook for NTES is positive due to robust fundamentals and international expansion potential. Risks include earnings volatility and competitive pressures in the gaming sector. Upside is supported by a $0.72 dividend and strong cash flow generation, though investors should monitor quarterly performance against expectations.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →